SAGE Therapeutics (SAGE) – Press Releases
-
Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
-
Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
-
Sage Therapeutics to Present at Upcoming March Investor Conferences
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024
-
Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference
-
Sage Therapeutics Announces Changes to Board of Directors
-
Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024
-
ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.
-
Sage Therapeutics to Present at Upcoming November Investor Conferences
-
Sage Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
-
Sage Therapeutics Announces U.S. Food and Drug Administration Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
-
Metals and Mining Virtual Investor Conference: Presentations Now Available for Online Viewing
-
Metals & Mining Virtual Investor Conference Agenda Announced for October 3rd- October 5th
-
Sage Therapeutics to Present at Upcoming September Investor Conferences
-
Bragar Eagel & Squire, P.C. Is Investigating DigitalOcean, and Sage and Encourages Investors to Contact the Firm
-
Sage Therapeutics Implements Strategic Reorganization to Support Plans for ZURZUVAE™ Commercial Launch and Pipeline Advancement
-
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
-
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics to Host Business Update Webcast and Announce Second Quarter Financial Results on Monday, August 7, 2023
-
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
-
Sage Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
-
Sage Therapeutics Announces First Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023
-
Sage Therapeutics to Present at the Stifel 2023 CNS Days
-
Sage Therapeutics Appoints Jessica Federer to Board of Directors
-
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
-
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
-
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
-
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
-
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
-
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
-
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
-
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
-
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
-
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
-
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
-
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
-
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
-
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Sage Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
-
Sage Therapeutics to Present at Upcoming August Investor Conferences
Back to SAGE Stock Lookup
